Skip to main content
. 2015 May 26;10(5):e0127524. doi: 10.1371/journal.pone.0127524

Fig 1. The kinetics of each specific substrate glucuronidation in pooled commercial, adjacent normal and HBV-positive HCC human liver microsomes.

Fig 1

(A) Metabolism kinetics of genistein in commercial, adjacent normaland HBV-positive HCC HLMs (n = 5). (B) Metabolism kinetics of zidovudine in commercial, adjacent normal and HBV-positive HCC HLMs (n = 5). (C) Metabolism kinetics of tamoxifen in commercial, adjacent normal and HBV-positive HCCHLMs (n = 5). (D) Metabolism kinetics of propofol in commercial, adjacent normal and HBV-positive HCC HLMs (n = 5). (E) Metabolism kinetics of SN-38 in commercial, adjacent normal and HBV-positive HCC HLMs (n = 5). Each data point represents the average of three determinations. Representative data from three independent experiments are shown as the mean ± S.D.